NTLA

Intellia Therapeutics, Inc.

Fundamental data last updated:November 6, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Biotechnology

Exchange

NASDAQ

County of HQ

United States

Next Earnings Date

Pending Announcement

Business Summary

NTLA's business model revolves around pioneering gene-editing therapies, aiming to revolutionize treatment paradigms. Their competitive moat lies in proprietary CRISPR technology, which offers a unique edge in precision medicine. By focusing on rare genetic disorders, they target niche markets with high unmet needs. This strategy not only drives potential cash flow but also fosters customer loyalty through groundbreaking therapeutic solutions.

 


VALUATION

P/E

-3.96

Market Cap ($M USD)

$1.87B

Forward P/E

1.53

PEG

0.20

PRICE TO SALES

31.37

PRICE TO BOOK

2.44

EV / EBITDA

-4.70

5-Year Average P/E

Free Cash Flow Yield

-18.68%

DCF Value

$-17.03

Graham Number

N/A

Price to FCF

-5.35

EV to FCF

-5.26

Earnings Yield

-22.50%

FCF Yield

-18.68%

DIVIDEND

Yield

0.00%

Annual Payout

$0.00

Payout Ratio

0.00%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

-$3.00

Next Year EPS Growth Estimate

-$3.20

Next Year Revenue Growth Estimate

$50.26M

Return on Equity (ROE)

-57.79%

FREE CASH FLOW

Operating Margin

-711.66%

Debt-to-Equity

0.10

Piotroski F-Score

4

Altman Z-Score

3.25

Return on Invested Capital (ROIC)

-52.86%

Current Ratio

6.65

Quick Ratio

6.65

Net Debt to EBITDA

0.08

Interest Coverage

0.00

Gross Profit margin

-46.48%

FCF PER SHARE

$-2.61

REVENUE PER SHARE

$0.45

Gainseekers Quantitative Analysis

Summary

NTLA’s valuation is a paradox wrapped in volatility. Recent pricing indicated it traded below its DCF Value, suggesting a potential mispricing by the market. The Forward P/E of 1.53 is strikingly low, hinting at expected growth, yet the negative Earnings Yield and ROIC of -52.86% paint a grim picture of current profitability. The Altman Z-score of 3.25 suggests financial stability, but the negative operating margins and return on equity raise red flags about management’s efficiency. This is a stock caught between promise and peril.

AI Exposure / Tech Reliance

Operating in the biotechnology sector, NTLA is inherently positioned to leverage AI and modern tech advancements. The industry's reliance on cutting-edge research and data analytics aligns well with AI-driven innovations. This positioning could enhance their drug development processes and operational efficiencies.

The Bull Case

For the optimistic investor, NTLA offers a compelling narrative of potential growth. The Forward PEG ratio of 0.20 suggests undervaluation relative to expected growth, a beacon for GARP investors. Despite negative margins, the Piotroski F-Score of 4 indicates some financial health, and the low Debt/Equity ratio of 0.10 underscores a conservative capital structure. The high sales growth projection further fuels the bullish case, hinting at future revenue expansion.

The Bear Case

However, the bear case is equally formidable. The Price/Sales ratio of 31.37 and Price/Book of 2.44 signal overvaluation, especially when juxtaposed with the negative FCF Yield and Price to FCF. The operating margin of -711.66% is a glaring weakness, reflecting severe inefficiencies. With the stock trading close to its 52-week high, technical overextension could be a risk, making it vulnerable to corrections.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Buy

Average Analyst Price Target

$20.71

Institutional Ownership %

1-Year Beta

1.80

Insider Buying % (6 Mo)

Distance to 52-Week High

38.74%

Distance to 52-Week Low

40.32%

EARNINGS SURPRISE %

-0.09%

50-DAY SMA

$12.23

200-DAY SMA

$13.07

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.